An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B

Citations

WEB OF SCIENCE

133
Citations

SCOPUS

149

초록

Background & Aims: Several models have recently been developed to predict risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). Our aims were to develop and validate an artificial intelligence-assisted prediction model of HCC risk. Methods: Using a gradient-boosting machine (GBM) algorithm, a model was developed using 6,051 patients with CHB who received entecavir or tenofovir therapy from 4 hospitals in Korea. Two external validation cohorts were independently established: Korean (5,817 patients from 14 Korean centers) and Caucasian (1,640 from 11 Western centers) PAGE-B cohorts. The primary outcome was HCC development. Results: In the derivation cohort and the 2 validation cohorts, cirrhosis was present in 26.9%–50.2% of patients at baseline. A model using 10 parameters at baseline was derived and showed good predictive performance (c-index 0.79). This model showed significantly better discrimination than previous models (PAGE-B, modified PAGE-B, REACH-B, and CU-HCC) in both the Korean (c-index 0.79 vs. 0.64–0.74; all p <0.001) and Caucasian validation cohorts (c-index 0.81 vs. 0.57–0.79; all p <0.05 except modified PAGE-B, p = 0.42). A calibration plot showed a satisfactory calibration function. When the patients were grouped into 4 risk groups, the minimal-risk group (11.2% of the Korean cohort and 8.8% of the Caucasian cohort) had a less than 0.5% risk of HCC during 8 years of follow-up. Conclusions: This GBM-based model provides the best predictive power for HCC risk in Korean and Caucasian patients with CHB treated with entecavir or tenofovir. Lay summary: Risk scores have been developed to predict the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B. We developed and validated a new risk prediction model using machine learning algorithms in 13,508 antiviral-treated patients with chronic hepatitis B. Our new model, based on 10 common baseline characteristics, demonstrated superior performance in risk stratification compared with previous risk scores. This model also identified a group of patients at minimal risk of developing HCC, who could be indicated for less intensive HCC surveillance.

키워드

antiviral treatmentchronic hepatitis Bdeep neural networkingHBVHCCliver cancerENTECAVIR TREATMENTSCORING SYSTEMVALIDATIONLAMIVUDINECIRRHOSISTHERAPYHISTORYSCORES
제목
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B
저자
Kim, H.Y.Lampertico, P.Nam, J.Y.Lee, H.-C.Kim, S.U.Sinn, D.H.Seo, Y.S.Lee, H.A.Park, S.Y.Lim, Y.-S.Jang, E.S.Yoon, Eileen LaurelKim, H.S.Kim, S.E.Ahn, S.B.Shim, J.-J.Jeong, S.W.Jung, Y.J.Sohn, Joo HyunCho, Y.K.Jun, Dae WonDalekos, G.N.Idilman, R.Sypsa, V.Berg, T.Buti, M.Calleja, J.L.Goulis, J.Manolakopoulos, S.Janssen, H.L.A.Jang, M.-J.Lee, Y.B.Kim, Y.J.Yoon, J.-H.Papatheodoridis, G.V.Lee, J.-H.
DOI
10.1016/j.jhep.2021.09.025
발행일
2022-02
유형
Article
저널명
Journal of Hepatology
76
2
페이지
311 ~ 318